Recent Updates
Recently added Catalysts

ARO-MAPT-

Phase 1

Alzheimer Disease | Small molecule | Neurology |Arrowhead Pharmaceuticals, Inc.|Last Updated: Jun 23, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment112
FDA Designations
No designations recorded
Clinical trial landscape

ARO-MAPT- · 1 trial · 2 indications

Phase 1 1
NCT07221344Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's DiseaseAlzheimer Disease
RECRUITING112 Analytics
PHASE1RECRUITING
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Alzheimer Disease
NCT07221344112
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Over Time
Through End of Study (EOS), Day 270
Secondary Endpoints
PK of ARO-MAPT-SC: Maximum Observed Plasma Concentration (Cmax)
Through 48 hours postdose
PK of ARO-MAPT-SC: Time to Maximum Plasma Concentration (Tmax)
Through 48 hours postdose
PK of ARO-MAPT-SC: Area Under the Plasma Concentration (AUC) Versus Time Curve From Time Zero to 24 Hours (AUC0-24)
Through 24 hours postdose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ARO-MAPT-SCEXPERIMENTALARO-MAPT-SC injection
PlaceboPLACEBO_COMPARATORSterile normal saline (0.9%)
Interventions
NameTypeDescription
ARO-MAPT-SCDRUG• single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection
PlaceboDRUG• calculated volume to match active treatment by SC administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 80 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria (All Participants): * Body mass index between 18.0 and 35.0 kilograms (kg)/square meter (m\^2) at Screening * Not pregnant or breast-feeding * Able and willing to provide written informed consent prior to the performance of any study specific procedures * Participants of childbea...

Countries:CanadaNew Zealand
Unlock Eligibility Criteria
Competitive Landscape -Alzheimer's Disease 66 trials (matched to "Alzheimer Disease")

Top 20 of 25 competitors

CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY9PHASE3KarXT, KarX-EC
Eli Lilly and CompanyLLY12PHASE3Donanemab, Dexamethasone
Biogen Inc.BIIB2PHASE3Lecanemab
Annovis Bio IncANVS1PHASE3buntanetap/posiphen
ACADIA Pharmaceuticals Inc.ACAD2PHASE3ACP-204
Novartis AG Sponsored ADRNVS2PHASE2VHB937
GSK plc Sponsored ADRGSK2PHASE2GSK4527226
Cognition Therapeutics, Inc.CGTX2PHASE2CT1812
Johnson & JohnsonJNJ1PHASE2JNJ-64042056
Merck & Co., Inc.MRK1PHASE2MK-2214
Lantheus Holdings IncLNTH2PHASE3Nilotinib BE
Acumen Pharmaceuticals, Inc.ABOS1PHASE2sabirnetug
Aclaris Therapeutics, Inc.ACRS1PHASE2ATI-045
IGC Pharma, Inc.IGC1PHASE2IGC-AD1-Active
Alnylam Pharmaceuticals, IncALNY2PHASE1ALN-5288
Arrowhead Pharmaceuticals, Inc.ARWR1PHASE1ARO-MAPT-
AC Immune SAACIU2PHASE1ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, ACI-24.060 at Dose A in Study Part 2
Denali Therapeutics Inc.DNLI1PHASE1DNL628
Alzamend Neuro, Inc.ALZN1PHASE1ALZN002 .
Voyager Therapeutics, Inc.VYGR1PHASE1VY7523
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJun 23, 2026NCT07221344lastUpdatePostDate: changed
LOWJun 23, 2026NCT07221344lastUpdatePostDate: changed
LOWMay 29, 2026NCT07221344lastUpdatePostDate: changed
LOWMay 29, 2026NCT07221344lastUpdatePostDate: changed
LOWMay 29, 2026NCT07221344lastUpdatePostDate: changed
LOWMay 26, 2026NCT07221344primaryCompletionDate: changed
LOWMay 24, 2026NCT07221344studyFirstPostDate: changed